AZD1222 - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the study vaccine (AZD1222) and to determine if it is safe and effective against COVID-19.

For more information or to sign up, visit us at:

What is the Condition Being Studied?

COVID-19 Vaccine

Who Can Participate in the Study?

-Adults that are at high-risk of getting COVID-19 (i.e essential workers)
-Generally healthy
-People over 55 years old and/or people of color are encouraged to participate

What is Involved?

If you choose to join this study, you will:
Be randomized (like flipping a coin) into Group 1 or Group 2
--Group 1 will get the study vaccine (AZD1222)
--Group 2 will get a placebo (harmless saltwater that is not active)
-Have up to 8 clinic visits
-Complete questionnaires
-Complete weekly symptom checks

Study Details

Full Title
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Principal Investigator
Pediatric Infectious Diseases Specialist
Protocol Number
IRB: PRO00106353
Phase III
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center